Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer

Charlotte Manogue; Elisa Ledet; A. Kumar Guddati; Brian Lewis; Oliver Sartor

doi:10.1634/theoncologist.2017-0450

Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer

Charlotte Manogue, Elisa Ledet, A. Kumar Guddati, Brian Lewis, Oliver Sartor

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Prostate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous-infusion 5-fluorouracil (5-FU) at a dose of 200 mg/m ² in a patient with rapidly progressive, heavily pretreated, metastatic castrate-resistant prostate cancer. Baseline prostate-specific antigen values declined from 1,890 ng/mL to <1 ng/mL after 5-FU therapy. We hypothesized that prostate-specific membrane antigen overexpression may result in cancer cells uniquely susceptible to antifolate therapies.

Original language	English (US)
Pages (from-to)	383-385
Number of pages	3
Journal	Oncologist
Volume	23
Issue number	3
DOIs	https://doi.org/10.1634/theoncologist.2017-0450
State	Published - Mar 2018
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1634/theoncologist.2017-0450

Cite this

@article{4814bac594064a86930658041c84fe84,

title = "Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer",

abstract = " Prostate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous-infusion 5-fluorouracil (5-FU) at a dose of 200 mg/m 2 in a patient with rapidly progressive, heavily pretreated, metastatic castrate-resistant prostate cancer. Baseline prostate-specific antigen values declined from 1,890 ng/mL to <1 ng/mL after 5-FU therapy. We hypothesized that prostate-specific membrane antigen overexpression may result in cancer cells uniquely susceptible to antifolate therapies.",

author = "Charlotte Manogue and Elisa Ledet and Guddati, {A. Kumar} and Brian Lewis and Oliver Sartor",

note = "Publisher Copyright: {\textcopyright} AlphaMed Press 2017",

year = "2018",

month = mar,

doi = "10.1634/theoncologist.2017-0450",

language = "English (US)",

volume = "23",

pages = "383--385",

journal = "Oncologist",

issn = "1083-7159",

publisher = "AlphaMed Press",

number = "3",

}

TY - JOUR

T1 - Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer

AU - Manogue, Charlotte

AU - Ledet, Elisa

AU - Guddati, A. Kumar

AU - Lewis, Brian

AU - Sartor, Oliver

N1 - Publisher Copyright: © AlphaMed Press 2017

PY - 2018/3

Y1 - 2018/3

N2 - Prostate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous-infusion 5-fluorouracil (5-FU) at a dose of 200 mg/m 2 in a patient with rapidly progressive, heavily pretreated, metastatic castrate-resistant prostate cancer. Baseline prostate-specific antigen values declined from 1,890 ng/mL to <1 ng/mL after 5-FU therapy. We hypothesized that prostate-specific membrane antigen overexpression may result in cancer cells uniquely susceptible to antifolate therapies.

AB - Prostate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous-infusion 5-fluorouracil (5-FU) at a dose of 200 mg/m 2 in a patient with rapidly progressive, heavily pretreated, metastatic castrate-resistant prostate cancer. Baseline prostate-specific antigen values declined from 1,890 ng/mL to <1 ng/mL after 5-FU therapy. We hypothesized that prostate-specific membrane antigen overexpression may result in cancer cells uniquely susceptible to antifolate therapies.

UR - http://www.scopus.com/inward/record.url?scp=85043395165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043395165&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2017-0450

DO - 10.1634/theoncologist.2017-0450

M3 - Article

C2 - 29259071

AN - SCOPUS:85043395165

SN - 1083-7159

VL - 23

SP - 383

EP - 385

JO - Oncologist

JF - Oncologist

IS - 3

ER -

Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this